These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 1311487)
1. Protective efficacy of virus-like particles for bluetongue disease. Roy P; French T; Erasmus BJ Vaccine; 1992; 10(1):28-32. PubMed ID: 1311487 [TBL] [Abstract][Full Text] [Related]
2. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection. Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887 [TBL] [Abstract][Full Text] [Related]
3. From genes to complex structures of bluetongue virus and their efficacy as vaccines. Roy P Vet Microbiol; 1992 Nov; 33(1-4):155-68. PubMed ID: 1336237 [TBL] [Abstract][Full Text] [Related]
4. Recombinant virus vaccine for bluetongue disease in sheep. Roy P; Urakawa T; Van Dijk AA; Erasmus BJ J Virol; 1990 May; 64(5):1998-2003. PubMed ID: 2157868 [TBL] [Abstract][Full Text] [Related]
5. Characterization of protection afforded by a bivalent virus-like particle vaccine against bluetongue virus serotypes 1 and 4 in sheep. Pérez de Diego AC; Athmaram TN; Stewart M; Rodríguez-Sánchez B; Sánchez-Vizcaíno JM; Noad R; Roy P PLoS One; 2011; 6(10):e26666. PubMed ID: 22046324 [TBL] [Abstract][Full Text] [Related]
6. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Roy P; Bishop DH; LeBlois H; Erasmus BJ Vaccine; 1994 Jul; 12(9):805-11. PubMed ID: 7975859 [TBL] [Abstract][Full Text] [Related]
7. Nature and duration of protective immunity to bluetongue virus infection. Roy P Dev Biol (Basel); 2003; 114():169-83. PubMed ID: 14677687 [TBL] [Abstract][Full Text] [Related]
8. Bluetongue virus serotype 8 virus-like particles protect sheep against virulent virus infection as a single or multi-serotype cocktail immunogen. Stewart M; Dubois E; Sailleau C; Bréard E; Viarouge C; Desprat A; Thiéry R; Zientara S; Roy P Vaccine; 2013 Jan; 31(3):553-8. PubMed ID: 23159460 [TBL] [Abstract][Full Text] [Related]
9. Vaccines against bluetongue in Europe. Savini G; MacLachlan NJ; Sanchez-Vizcaino JM; Zientara S Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):101-20. PubMed ID: 17765305 [TBL] [Abstract][Full Text] [Related]
10. Replication-Deficient Particles: New Insights into the Next Generation of Bluetongue Virus Vaccines. Celma CC; Stewart M; Wernike K; Eschbaumer M; Gonzalez-Molleda L; Breard E; Schulz C; Hoffmann B; Haegeman A; De Clercq K; Zientara S; van Rijn PA; Beer M; Roy P J Virol; 2017 Jan; 91(1):. PubMed ID: 27795442 [TBL] [Abstract][Full Text] [Related]
12. Determination of the minimum protective dose for bluetongue virus serotype 2 and 8 vaccines in sheep. Modumo J; Venter EH J S Afr Vet Assoc; 2012 Aug; 83(1):17. PubMed ID: 23327131 [TBL] [Abstract][Full Text] [Related]
13. Genetically engineered multi-component virus-like particles as veterinary vaccines. Pearson LD; Roy P Immunol Cell Biol; 1993 Oct; 71 ( Pt 5)():381-9. PubMed ID: 8270267 [TBL] [Abstract][Full Text] [Related]
14. Validation of a novel approach for the rapid production of immunogenic virus-like particles for bluetongue virus. Stewart M; Bhatia Y; Athmaran TN; Noad R; Gastaldi C; Dubois E; Russo P; Thiéry R; Sailleau C; Bréard E; Zientara S; Roy P Vaccine; 2010 Apr; 28(17):3047-54. PubMed ID: 19887134 [TBL] [Abstract][Full Text] [Related]
15. Duration of protective immunity after a single vaccination with a live attenuated bivalent bluetongue vaccine. Zhugunissov K; Yershebulov Z; Barakbayev K; Bulatov Y; Taranov D; Amanova Z; Abduraimov Y Vet Res Commun; 2015 Dec; 39(4):203-10. PubMed ID: 26280208 [TBL] [Abstract][Full Text] [Related]
16. Beta-propiolactone inactivated bivalent bluetongue virus vaccine containing Montanide ISA-71VG adjuvant induces long-term immune response in sheep against serotypes 4 and 16 even after 3 years of controlled vaccine storage. Zhugunissov K; Bulatov Y; Taranov D; Yershebulov Z; Koshemetov Z; Zhunushov A; Renukaradhya GJ; Tabynov K; Abduraimov Y Vet Microbiol; 2018 Nov; 226():23-30. PubMed ID: 30389040 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of vaccination for bluetongue virus serotype 8 performed shortly before challenge and implications for animal trade. Spedicato M; Lorusso A; Salini R; Gennaro AD; Leone A; Teodori L; Casaccia C; Portanti O; Calistri P; Giovannini A; Savini G Prev Vet Med; 2017 Jan; 136():49-55. PubMed ID: 28010907 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the immune response afforded by a subunit vaccine candidate against bluetongue virus in mice and sheep. Mohamed DKA; Du J; Gao S; Tian Z; Zhang G; Huang D; Du R; Kang B; Liu G; Luo J; Yin H Vet Microbiol; 2018 Jun; 219():40-48. PubMed ID: 29778203 [TBL] [Abstract][Full Text] [Related]